Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based biopharmaceutical companies Cephalon and Ception Therapeutics have signed an agreement providing Cephalon with an option to purchase all outstanding capital stock of Ception.
Subscribe to our email newsletter
Under the terms of the option agreement, Cephalon will pay Ception a $100 million upfront option payment. Ception’s lead product is reslizumab.
Reslizumab is a humanized monoclonal antibody against interleukin-5 currently in a Phase IIb/III clinical trial for the treatment of pediatric eosinophilic esophagitis (EE) and in a Phase II clinical trial for the treatment of eosinophilic asthma in adults.
Ception also has an established program to discover small molecule, orally active, anti-tumor necrosis factor receptor agents.
Cephalon may exercise its option at any time prior to expiration of a specified period after receipt of the final study report for the pediatric EE clinical trial. If Cephalon exercises its option, the company will purchase all of the outstanding capital stock of Ception for $250 million. Ception shareholders could receive additional payments related to clinical and regulatory milestones.
Frank Baldino, Jr, chairman and CEO of Cephalon, said: “This deal builds on our heritage as a biotech company and creates the opportunity for Cephalon to introduce its first biologic into the market. The addition of biologics, which have a longer commercial life, will add higher value products to our portfolio. Strategically the agreement aligns with our development of products that address patient need, which are first-in-class and focus on specialty pharmaceutical markets.”